Efficacy of bosentan in the treatment of Raynaud’s phenomenon in patients with systemic sclerosis never treated with prostanoids

The objective of this study was to evaluate the efficacy of the endothelin receptor antagonist, bosentan, in patients with Raynaud’s phenomenon secondary to systemic sclerosis never treated with prostanoids and without digital ulcers. The study design is a preliminary, prospective open label trial....

Full description

Bibliographic Details
Main Authors: S. Parisi, M. Bruzzone, C. Centanaro Di Vittorio, A. Laganà, C.L. Peroni, E. Fusaro
Format: Article
Language:English
Published: PAGEPress Publications 2014-03-01
Series:Reumatismo
Subjects:
Online Access:http://www.reumatismo.org/index.php/reuma/article/view/691